ClinicalTrials.gg
CompletedNCT03430583FALDUpdated Oct 14, 2025Results posted

Evaluation of Fontan-associated Hepatic Stiffness and the Efficacy of Udenafil in Reducing Liver Stiffness

A Phase 3 interventional study of Udenafil in Single Ventricle Heart Disease, sponsored by Mezzion Pharma Co. Ltd. Completed at 17 sites in 2 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-10-14.

Sponsored by Mezzion Pharma Co. Ltd · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
88
Allocation
Non-randomized
Ages
12 Years and older
Sex
All
01

Study summary

A study to evaluate the efficacy of MZ101 therapy in reducing liver stiffness.

Read the detailed description

This is open-label, long-term prospective study in a cohort of Fontan subjects taking drug daily for one year. The study will determine the scope of hepatic stiffness in the cohort by ultrasound and magnetic resonance imaging elastography and evaluate MZ101 pharmacotherapy as a potentially efficacious treatment to reduce liver stiffness.

02

Conditions studied

  • Single Ventricle Heart Disease

Keywords

  • Fontan
  • Ultrasound Shear Wave Elastography
  • Magnetic Resonance Imaging Elastography
03

In context

Lead sponsor

Mezzion Pharma Co. Ltd is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Enrollment in on-going Phase 3 Open-Label Safety Study
  2. Informed assent from subject, from parent/legal guardian as appropriate

Exclusion criteria

Exclusion Criteria:

  1. Non-enrollment in the on-going Phase 3 Open-Label Study
  2. Subjects with for MRI (these subjects will be excluded from the MRI component of this study)
  3. Other exclusionary criteria will match those used for the Open-Label Safety Study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
88 participants (actual)

Study arms

  • Experimental
    Udenafil Continuation (U+)

    Subjects who were receiving Udenafil 87.5 mg BID in FUEL study prior to enrolling to this study (FALD).

    Drug: Udenafil

  • Experimental
    Udenafil Naive (U-)

    Subjects who were receiving Placebo BID in FUEL study prior to enrolling to this study (FALD).

    Drug: Udenafil

Interventions

  • Open-label extension with Udenafil 87.5 mg BID treatment for 52 weeks.

06

What researchers measure

Primary outcomes

  1. Effect of Udenafil 87.5 mg BID Treatment on Liver Stiffness in Udenafil Continuation and Naive Groups After 52 Weeks, as Determined by Ultrasound Shear Wave Elastography

    Liver stiffness was measured at baseline and 52 weeks using Ultrasound Shear Wave Elastography (USWE) separately in Udenafil Continuation (U+) and Udenafil Naive (U-) groups. A decrease in value indicates a decrease in liver stiffness.

    Time frame: 52 weeks

  2. Effect of Udenafil 87.5 mg BID Treatment on Liver Stiffness in Udenafil Continuation and Naive Groups After 52 Weeks, as Determined by Magnetic Resonance Elastography

    Liver stiffness was measured at baseline and 52 weeks using Magnetic Resonance Elastography (MRE) separately in Udenafil Continuation (U+) and Udenafil Naive (U-) groups. A decrease in value indicates a decrease in liver stiffness.

    Time frame: 52 weeks

Secondary outcomes

  1. Effect of Udenafil 87.5 mg BID on Enhanced Liver Fibrosis (ELF) Score After 52 Weeks of Treatment

    Overall ELF score. ELF score is based on the serum levels of hyaluronic acid (HA), amino-terminal propeptide of type III collagen (PIIINP), and tissue inhibitor of metalloproteinase-1 (TIMP-1), and calculated using the following formula: ELF score= 2.494+0.846 In(CHA)+0.391 In(CPIIINP)+0.391 In(CTIMP-1). The levels of each component were as assessed individually and as part of the calculated ELF score as continuous variables. The normal range in healthy subjects ≤20 years of age is 6.9 - 8.8. Correlations between ELF and the degree of liver fibrosis have not been established in patients with Fontan circulation, however, a decrease in ELF score is associated with improved liver health in other disease states.

    Time frame: 52 weeks

  2. Effect of Udenafil 87.5 mg BID on Brain Natriuretic Peptide After 52 Weeks of Treatment

    Brain Natriuretic Peptide (BNP) was measured at baseline and 52 weeks of treatment. BNP is a biomarker of overall cardiac function across a variety of disease states. A decrease in value is associated with improved cardiac function.

    Time frame: 52 weeks

07

Results

Posted Sep 18, 2025

Participant flow

Participant flow — Overall Study
MilestoneUdenafil Continuation (U+)Udenafil Naive (U-)
Started3652
Completed3345
Not completed37

Outcome measures

PrimaryEffect of Udenafil 87.5 mg BID Treatment on Liver Stiffness in Udenafil Continuation and Naive Groups After 52 Weeks, as Determined by Ultrasound Shear Wave Elastography

Liver stiffness was measured at baseline and 52 weeks using Ultrasound Shear Wave Elastography (USWE) separately in Udenafil Continuation (U+) and Udenafil Naive (U-) groups. A decrease in value indicates a decrease in liver stiffness.

Time frame:
52 weeks
Reported as:
Mean · meters per second
Effect of Udenafil 87.5 mg BID Treatment on Liver Stiffness in Udenafil Continuation and Naive Groups After 52 Weeks, as Determined by Ultrasound Shear Wave Elastography
meters per secondUdenafil Continuation (U+)Udenafil Naive (U-)Total Udenafil
Baseline1.91 ± 0.3802.02 ± 0.4501.97 ± 0.422
Week 521.86 ± 0.2881.96 ± 0.3491.92 ± 0.325
PrimaryEffect of Udenafil 87.5 mg BID Treatment on Liver Stiffness in Udenafil Continuation and Naive Groups After 52 Weeks, as Determined by Magnetic Resonance Elastography

Liver stiffness was measured at baseline and 52 weeks using Magnetic Resonance Elastography (MRE) separately in Udenafil Continuation (U+) and Udenafil Naive (U-) groups. A decrease in value indicates a decrease in liver stiffness.

Time frame:
52 weeks
Reported as:
Mean · kiloPascal (kPa)
Effect of Udenafil 87.5 mg BID Treatment on Liver Stiffness in Udenafil Continuation and Naive Groups After 52 Weeks, as Determined by Magnetic Resonance Elastography
kiloPascal (kPa)Udenafil Continuation (U+)Udenafil Naive (U-)Total Udenafil
Baseline5.26 ± 0.9275.26 ± 1.4535.26 ± 1.173
Week 524.95 ± 1.0805.50 ± 1.5505.20 ± 1.322
SecondaryEffect of Udenafil 87.5 mg BID on Enhanced Liver Fibrosis (ELF) Score After 52 Weeks of Treatment

Overall ELF score. ELF score is based on the serum levels of hyaluronic acid (HA), amino-terminal propeptide of type III collagen (PIIINP), and tissue inhibitor of metalloproteinase-1 (TIMP-1), and calculated using the following formula: ELF score= 2.494+0.846 In(CHA)+0.391 In(CPIIINP)+0.391 In(CTIMP-1). The levels of each component were as assessed individually and as part of the calculated ELF score as continuous variables. The normal range in healthy subjects ≤20 years of age is 6.9 - 8.8. Correlations between ELF and the degree of liver fibrosis have not been established in patients with Fontan circulation, however, a decrease in ELF score is associated with improved liver health in other disease states.

Time frame:
52 weeks
Reported as:
Mean · score on a scale
Effect of Udenafil 87.5 mg BID on Enhanced Liver Fibrosis (ELF) Score After 52 Weeks of Treatment
score on a scaleUdenafil Continuation (U+)Udenafil Naive (U-)Total Udenafil
Baseline10.58 ± 0.91510.45 ± 0.85310.50 ± 0.877
Week 529.72 ± 0.8189.79 ± 0.7509.76 ± 0.776
SecondaryEffect of Udenafil 87.5 mg BID on Brain Natriuretic Peptide After 52 Weeks of Treatment

Brain Natriuretic Peptide (BNP) was measured at baseline and 52 weeks of treatment. BNP is a biomarker of overall cardiac function across a variety of disease states. A decrease in value is associated with improved cardiac function.

Time frame:
52 weeks
Reported as:
Mean · pg/ml
Effect of Udenafil 87.5 mg BID on Brain Natriuretic Peptide After 52 Weeks of Treatment
pg/mlUdenafil Continuation (U+)Udenafil Naive (U-)Total Udenafil
Baseline16.89 ± 13.72617.20 ± 13.42817.07 ± 13.464
Week 5220.31 ± 18.33620.78 ± 19.16520.59 ± 18.698

Adverse events

Collected over Not applicable, as all safety information was collected in the Study PHN-Udenafil-03 (parent study) and will be reported as part of the results from that study. All-Cause Mortality, Serious, and Other (Not Including Serious) Adverse Events were not monitored/assessed as part of Study PHN-Udenafil-04.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Udenafil 87.5 mg BID———

Baseline characteristics

Age, Customized
Age, Customized(years)Udenafil Continuation (U+)Udenafil Naive (-)Total
Mean15.80 ± 1.99215.16 ± 1.96115.4 ± 2.0
Sex: Female, Male
Sex: Female, Male(Participants)Udenafil Continuation (U+)Udenafil Naive (-)Total
Female131932
Male233356
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Udenafil Continuation (U+)Udenafil Naive (-)Total
Hispanic or Latino336
Not Hispanic or Latino324880
Unknown or Not Reported112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Udenafil Continuation (U+)Udenafil Naive (-)Total
American Indian or Alaska Native011
Asian224
Native Hawaiian or Other Pacific Islander000
Black or African American246
White324375
More than one race000
Unknown or Not Reported022
Body Mass Index (BMI)
Body Mass Index (BMI)(kilograms per meter squared)Udenafil Continuation (U+)Udenafil Naive (-)Total
Mean21.9 ± 4.55221.4 ± 4.17421.6 ± 4.314
Height
Height(cm)Udenafil Continuation (U+)Udenafil Naive (-)Total
Mean162.08 ± 10.277164.89 ± 8.936163.74 ± 9.552
Weight
Weight(Kg)Udenafil Continuation (U+)Udenafil Naive (-)Total
Mean57.48 ± 13.07858.42 ± 13.23858.03 ± 13.105
Liver Stiffness by Ultrasound Shear Wave Elastography (USWE)
Liver Stiffness by Ultrasound Shear Wave Elastography (USWE)(meters/sec)Udenafil Continuation (U+)Udenafil Naive (-)Total
Mean1.91 ± 0.3802.02 ± 0.4501.97 ± 0.422

3 further baseline measures are reported on the registry.

08

Study locations

17 sites
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Nemours Cardiac Center/Alfred I. duPont Hospital for Children
    Wilmington, Delaware 19803, United States
  • Children's National Medical Center
    Washington D.C., District of Columbia 20008, United States
  • Children's Healthcare of Atlanta
    Atlanta, Georgia 30322, United States
  • Children's Mercy Hospital
    Kansas City, Kansas 64108, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • University of Michigan Congenital Heart Center
    Ann Arbor, Michigan 48109-4204, United States
  • Children's Mercy Hospital Kansas City
    Kansas City, Missouri 64108, United States
  • University of Nebraska Children's Hospital and Medical Center
    Omaha, Nebraska 68114, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Texas Children's Hospital
    Houston, Texas 77030, United States
  • Primary Children's Medical Hospital/Dept. of Pediatric Cardiology
    Salt Lake City, Utah 84113, United States
  • Children's Hospital of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • The Hospital for Sick Children
    Toronto, Ontario ON M5G 1X8, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in Sep 2020, 30 months.

Results were first posted in Sep 2025, 5 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2018
First posted
Feb 13, 2018
StartActual
Feb 20, 2018
Primary completionActual
Sep 15, 2020
CompletionActual
Sep 16, 2020
Results first posted
Sep 18, 2025
Last update
Oct 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03430583
Lead sponsor
Mezzion Pharma Co. Ltd
Responsible party
Sponsor
First posted
Feb 13, 2018
Start date
Feb 20, 2018
Primary completion
Sep 15, 2020
Completion
Sep 16, 2020
Results posted
Sep 18, 2025
Last update
Oct 14, 2025

Study contacts

David J Goldberg, MD
principal investigator · Children's Hospital of Philadelphia
Kurt R Schumacher, MD
principal investigator · University of Michigan Congenital Heart Center/C.S. Mott Children's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Udenafil

Start the discussion